Immediate Impact

1 by Nobel laureates 1 from Science/Nature 55 standout
Sub-graph 1 of 23

Citing Papers

Targeting the tumour vasculature: from vessel destruction to promotion
2024 Standout
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
2022 Standout
3 intermediate papers

Works of M. Kulke being referenced

A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC).
2010
A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs)
2005

Author Peers

Author Last Decade Papers Cites
M. Kulke 183 126 85 116 13 350
A. Hackshaw 234 160 120 52 12 372
Matthias Ebert 235 124 78 102 17 372
Pamela Sighinolfi 163 128 17 96 14 378
Kyung Kee Baek 216 41 70 87 13 393
Tiffany Valone 292 176 111 100 16 360
Akihito Nishio 133 33 57 77 18 373
Christine Challen 186 30 110 212 13 372
K.D. Zang 69 109 94 144 13 328
Jonathan Rock 181 102 40 43 15 363
Sara M. Kloft‐Nelson 113 27 29 124 13 324

All Works

Loading papers...

Rankless by CCL
2026